Mirum Pharmaceuticals’ Atebrioz has received FDA approval for fibrodysplasia ossificans progressiva (FOP), extending the company’s rare-disease franchise with a third approved option for the condition. Mirum acquired Atebrioz from Incyte earlier this year, positioning the product as an additional treatment lever for a disease marked by progressive soft-tissue bone formation.